$The Denver Tube Combined with Antiviral Drugs In the Treatment of HBV-related Cirrhosis with Refractory Ascites: A Report of Three Cases$

The Denver Tube Combined with Antiviral Drugs In the Treatment of HBV-related Cirrhosis with Refractory Ascites: A Report of Three Cases

Treatment of nucleos(t)ide antiviral drugs for decompensated HBV-related cirrhosis can significantly improve the prognosis. But those patients with refractory ascites possibly deteriorate due to the complications of ascites before any benefit from anti-viral drugs could be observed. Therefore, it is...

Full description

Bibliographic Details
Main Authors:	Wang Xiao-jin, Shi Li-qin, Fu Qing-chun, Ni Liu-da, Zhou Feng, Chen Jin-wei, Chen Cheng-wei
Format:	Article
Language:	English
Published:	Sciendo 2014-03-01
Series:	Infection International
Subjects:	Cirrhosis decompensation Ascites Denver tube Nucleos(t)ide analogue
Online Access:	http://www.degruyter.com/view/j/ii.2014.3.issue-1/ii-2017-0073/ii-2017-0073.xml?format=INT

Similar Items

Factors predicting outcomes of hepatitis B-related cirrhosis patients with long-term antiviral therapy
by: Chih-Lin Lin, et al.
Published: (2020-10-01)

Antiviral Effects of Different Nucleos(t)ide Antiviral Drugs in Patients with Decompensated Hepatitis B Virus-Related Cirrhosis
by: Lei CAI, et al.
Published: (2016-09-01)

Malnutrition is related to a higher frequency of serious complications in patients with cirrhosis
by: E. Pérez-Reyes, et al.
Published: (2016-01-01)

Impact of antiviral therapy with nucleos(t)ide analog on survival of patients with HBV-related small hepatocellular carcinomas
by: Wei Y, et al.
Published: (2019-09-01)

Granulocyte colony stimulating factor: A potential therapeutic rescue in severe alcoholic hepatitis and decompensated cirrhosis
by: Sahaj Rathi, et al.
Published: (2021-01-01)

A Latin American survey on demographic aspects of hospitalized, decompensated cirrhotic patients and the resources for their management
by: Julio D. Vorobioff, et al.
Published: (2020-07-01)

Spontaneous bacterial peritonitis in a 45-year-old man with ethanolic liver cirrhosis
by: Roxana Mirică, et al.
Published: (2020-06-01)

Liver stiffness measurement at complete virological response in hepatoma prediction for HBV‐related cirrhosis patient with potent antiviral agent
by: Jing‐Houng Wang, et al.
Published: (2019-11-01)

Extracorporal modified ascitic fluid reinfusion in treatment of resistant ascites in liver cirrhosis
by: I. E. Onnintsev, et al.
Published: (2017-06-01)

Short‐term intraperitoneal catheters: An ambulatory care intervention for refractory ascites secondary to cirrhosis during COVID‐19
by: Natalie LY Ngu, et al.
Published: (2021-10-01)

KASL clinical practice guidelines for liver cirrhosis: Ascites and related complications
Published: (2018-09-01)

The First Finding of Cirrhosis: Hepatic Hydrothorax Caused by Absence of Ascites
by: Yahya Atayan, et al.
Published: (2015-06-01)

Chylous ascites in cirrhosis-A case report
by: S Laudari, et al.
Published: (2012-09-01)

Comparison of intermittent drainage of ascites and diuretic therapy for cirrhosis patients with tense ascites
by: Jun-feng Chen, et al.
Published: (2017-01-01)

Lamivudine: fading into the mists of time
by: Jonggi Choi, et al.
Published: (2017-12-01)

Anemia and Systemic Inflammation Rather than Arterial Circulatory Dysfunction Predict Decompensation of Liver Cirrhosis
by: Christina Bothou, et al.
Published: (2020-04-01)

Comparison of anti-HBV regimen with or without adefovir on hepatocellular carcinoma development of Chronic hepatitis B patients with compensated cirrhosis: a retrospective cohort study
by: Jing Sun, et al.
Published: (2018-05-01)

HBV and HCV Therapy
by: Massimo Colombo, et al.
Published: (2009-10-01)

Absolute quantification of microparticles by flow cytometry in ascites of patients with decompensated cirrhosis: a cohort study
by: Cornelius Engelmann, et al.
Published: (2017-09-01)

Patient adherence to antiviral treatment for chronic hepatitis B and C: a systematic review
by: Faydra I. Lieveld, et al.
Published: (2013-05-01)

Clinical Features of Refractory Ascites in Outpatients
by: Wanda Regina Caly, et al.

Transjugular intrahepatic portosystemic shunt for chylous ascites in a patient with recurrent cirrhosis following liver transplantation
by: Jason T. Salsamendi, MD, et al.
Published: (2017-03-01)

Tertiary Prevention of HCC in Chronic Hepatitis B or C Infected Patients
by: Wei Teng, et al.
Published: (2021-04-01)

A case of refractory ascites
by: Loris Varvello, et al.
Published: (2015-10-01)

Combination with portosystemic shunt occlusion and antiviral therapy improves prognosis of decompensated cirrhosis
by: Hideyuki Tamai, et al.
Published: (2020-08-01)

Genotyping of HBV and tracking of resistance mutations in treatment-naïve patients with chronic hepatitis B
by: Pacheco SR, et al.
Published: (2017-07-01)

A Hepatitis C Virus-Associated Decompensated Cirrhotic Patient Who Showed the Disappearance of Hepatic Encephalopathy, Ascites, and Pleural Effusion by Antiviral Therapy with Sofosbuvir/Velpatasvir
by: Kazuo Tarao, et al.
Published: (2021-04-01)

Tunneled Peritoneal Catheter for Refractory Ascites in Cirrhosis: A Randomized Case-Series
by: Nina Kimer, et al.
Published: (2020-10-01)

Recommendations of management of adult patients with ascites due to cirrhosis: update 2012
by: YANG Li
Published: (2013-09-01)

A Better Antiviral Efficacy Found in Nucleos(t)ide Analog (NA) Combinations with Interferon Therapy than NA Monotherapy for HBeAg Positive Chronic Hepatitis B: A Meta-Analysis
by: Wei Wei, et al.
Published: (2015-08-01)

Laminin concentration in ascites of patients with hepatic cirrhosis and peritoneal carcinomatosis
by: R.M. Catarino, et al.
Published: (2005-02-01)

Long-term outcomes of hepatitis B virus-related cirrhosis treated with nucleos(t)ide analogs
by: Ming-Chao Tsai, et al.
Published: (2017-07-01)

The potential benefit managing ascites due to cirrhosis using an integrative medicine approach
by: LIU Chenghai
Published: (2013-04-01)

Management of refractory cirrhotic ascites: challenges and solutions
by: Fukui H, et al.
Published: (2018-07-01)

Evolution of antiviral treatment chronic for hepatitis B, C and D
by: K. V. Zhdanov, et al.
Published: (2014-09-01)

Serum and Ascitic Fluid Superoxide Dismutase and Malondialdehyde Levels in Patients with Cirrhosis
by: Ugur Coskun, et al.
Published: (2008-01-01)

Expert consensus on TCM diagnosis and treatment of ascites due to cirrhosis (2017)
by: Branch of Gastrointestinal Diseases, China Association of Chinese Medicine
Published: (2017-09-01)

The Yin and the Yang of Treatment for Chronic Hepatitis B—When to Start, When to Stop Nucleos(t)ide Analogue Therapy
by: Samuel Hall, et al.
Published: (2020-08-01)

Durability after discontinuation of nucleos(t)ide therapy in chronic HBeAg negative hepatitis patients
by: Young Jip Kim, et al.
Published: (2013-09-01)

Is alanine aminotransferase flare-up in nucleos(t)ide analogue treatment of chronic hepatitis B a promising, rather than a devastating, sign?
by: Nae-Yun Heo
Published: (2017-06-01)